Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

• Oramed Pharmaceuticals Inc. has entered into definitive agreements to spin off its Protein Oral Delivery (POD) technology into a new joint venture, OraTech Pharmaceuticals Inc., in collaboration with Hefei Tianhui Biotech Co., Ltd. (HTIT).

• Oramed and HTIT will contribute a combined $75 million to support the venture’s development, commercialization, and clinical programs.

Oramed Pharmaceuticals Inc. has announced the formation of a new joint venture, OraTech Pharmaceuticals Inc., to advance its Protein Oral Delivery (POD) technology. The agreement, made in partnership with Hefei Tianhui Biotech Co., Ltd. (HTIT), is structured to accelerate the development and commercialization of Oramed’s oral insulin candidate, ORMD-0801, and other POD-based drug delivery solutions.

As part of the transaction, Oramed will transfer its proprietary oral insulin technology and additional pipeline assets to OraTech. Oramed shareholders will receive a majority equity stake in the new entity, giving them a direct interest in its future performance.

The agreement includes a $75 million combined capital investment from Oramed and HTIT. Part of this funding will be allocated to a supply agreement, supporting key manufacturing and development efforts. This financial backing aims to strengthen OraTech’s clinical programs, including the planned reinitiation of a pivotal Phase 3 clinical trial for oral insulin in the United States.

“OraTech will be singularly focused on bringing oral insulin to market and unlocking the broader potential of oral drug delivery for additional therapeutic targets,” said Nadav Kidron, CEO of Oramed. He emphasized the role of HTIT’s manufacturing capabilities in ensuring a scalable and efficient supply chain.

OraTech will leverage HTIT’s expertise in capsule production and cost-effective manufacturing to support clinical trials and commercial scale-up. With a dedicated focus on oral insulin and broader POD-based therapeutics, the new venture aims to advance innovative treatments for diabetes and other chronic diseases.